171 related articles for article (PubMed ID: 33184772)
1. Risk Score Model for Liver Transplant Outcomes after Preoperative Locoregional Therapy for Hepatocellular Carcinoma.
Bhatti ABH; Hassan M; Rana A; Khan NY; Khan ZA; Zia HH
J Gastrointest Cancer; 2022 Mar; 53(1):84-90. PubMed ID: 33184772
[TBL] [Abstract][Full Text] [Related]
2. When to call it off: defining transplant candidacy limits in liver donor liver transplantation for hepatocellular carcinoma.
Bhatti ABH; Qureshi AI; Tahir R; Dar FS; Khan NY; Zia HH; Riyaz S; Rana A
BMC Cancer; 2020 Aug; 20(1):754. PubMed ID: 32787864
[TBL] [Abstract][Full Text] [Related]
3. Younger age and presence of macrovascular invasion were independent significant factors associated with poor disease-free survival in hepatocellular carcinoma patients undergoing living donor liver transplantation.
Wai CT; Woon WA; Tan YM; Lee KH; Tan KC
Transplant Proc; 2012 Mar; 44(2):516-9. PubMed ID: 22410059
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation.
Choi HJ; Kim DG; Na GH; Han JH; Hong TH; You YK
World J Gastroenterol; 2013 Aug; 19(29):4737-44. PubMed ID: 23922471
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria.
Kim JM; Kwon CH; Joh JW; Choi MS; Lee JH; Koh KC; Paik SW; Kim GS; Kim SJ; Lee SK; Yoo BC
Transplant Proc; 2012 Mar; 44(2):403-8. PubMed ID: 22410028
[TBL] [Abstract][Full Text] [Related]
6. Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria.
Kardashian A; Florman SS; Haydel B; Ruiz RM; Klintmalm GB; Lee DD; Taner CB; Aucejo F; Tevar AD; Humar A; Verna EC; Halazun KJ; Chapman WC; Vachharajani N; Hoteit M; Levine MH; Nguyen MH; Melcher ML; Langnas AN; Carney CA; Mobley C; Ghobrial M; Amundsen B; Markmann JF; Sudan DL; Jones CM; Berumen J; Hemming AW; Hong JC; Kim J; Zimmerman MA; Nydam TL; Rana A; Kueht ML; Fishbein TM; Markovic D; Busuttil RW; Agopian VG
Hepatology; 2020 Dec; 72(6):2014-2028. PubMed ID: 32124453
[TBL] [Abstract][Full Text] [Related]
7. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
[TBL] [Abstract][Full Text] [Related]
8. Effects of loco regional treatments before living donor liver transplantation on overall survival and recurrence-free survival in South Korean patients with hepatocellular carcinoma.
Na GH; Kim EY; Hong TH; You YK; Kim DG
HPB (Oxford); 2016 Jan; 18(1):98-106. PubMed ID: 26776857
[TBL] [Abstract][Full Text] [Related]
9. Liver Imaging-Reporting and Data System treatment response algorithm predicts postsurgical recurrence in locoregional therapy-treated hepatocellular carcinoma.
Youn SY; Kim B; Kim DH; Choi HJ; Sung PS; Choi JI
Eur Radiol; 2022 Sep; 32(9):6270-6280. PubMed ID: 35348864
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of des-γ-carboxyl prothrombin in living-donor liver transplantation for recurrent hepatocellular carcinoma.
Harimoto N; Yoshida Y; Kurihara T; Takeishi K; Itoh S; Harada N; Tsujita E; Yamashita YI; Uchiyama H; Soejima Y; Ikegami T; Yoshizumi T; Kawanaka H; Ikeda T; Shirabe K; Saeki H; Oki E; Kimura Y; Maehara Y
Transplant Proc; 2015 Apr; 47(3):703-4. PubMed ID: 25819732
[TBL] [Abstract][Full Text] [Related]
11. Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium.
Agopian VG; Harlander-Locke MP; Ruiz RM; Klintmalm GB; Senguttuvan S; Florman SS; Haydel B; Hoteit M; Levine MH; Lee DD; Taner CB; Verna EC; Halazun KJ; Abdelmessih R; Tevar AD; Humar A; Aucejo F; Chapman WC; Vachharajani N; Nguyen MH; Melcher ML; Nydam TL; Mobley C; Ghobrial RM; Amundsen B; Markmann JF; Langnas AN; Carney CA; Berumen J; Hemming AW; Sudan DL; Hong JC; Kim J; Zimmerman MA; Rana A; Kueht ML; Jones CM; Fishbein TM; Busuttil RW
Ann Surg; 2017 Sep; 266(3):525-535. PubMed ID: 28654545
[TBL] [Abstract][Full Text] [Related]
12. Incorporating Tumor Biology to Predict Hepatocellular Carcinoma Recurrence in Patients Undergoing Living Donor Liver Transplantation Using Expanded Selection Criteria.
Bhangui P; Saigal S; Gautam D; Piplani T; Choudhary N; Chaudhary R; Yadav S; Thiagarajan S; Rastogi A; Saraf N; Nundy S; Soin AS
Liver Transpl; 2021 Feb; 27(2):209-221. PubMed ID: 33253492
[TBL] [Abstract][Full Text] [Related]
13. Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience.
Lee KW; Yi NJ; Suh KS
Transplantation; 2014 Apr; 97 Suppl 8():S20-3. PubMed ID: 24849825
[TBL] [Abstract][Full Text] [Related]
14. Living donor liver transplantation for advanced hepatocellular carcinoma including macrovascular invasion.
Bhatti ABH; Naqvi W; Khan NY; Zia HH; Dar FS; Khan ZA; Rana A
J Cancer Res Clin Oncol; 2022 Jan; 148(1):245-253. PubMed ID: 34117916
[TBL] [Abstract][Full Text] [Related]
15. Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients.
Agopian VG; Morshedi MM; McWilliams J; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Hiatt JR; Busuttil RW
Ann Surg; 2015 Sep; 262(3):536-45; discussion 543-5. PubMed ID: 26258323
[TBL] [Abstract][Full Text] [Related]
16. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
17. Living-donor liver transplantation associated with higher incidence of hepatocellular carcinoma recurrence than deceased-donor liver transplantation.
Park MS; Lee KW; Suh SW; You T; Choi Y; Kim H; Hong G; Yi NJ; Kwon CH; Joh JW; Lee SK; Suh KS
Transplantation; 2014 Jan; 97(1):71-7. PubMed ID: 24056623
[TBL] [Abstract][Full Text] [Related]
18. Living donor liver transplantation or hepatic resection combined with intraoperative radiofrequency ablation for Child-Pugh A hepatocellular carcinoma patient with Multifocal Tumours Meeting the University of California San Francisco (UCSF) criteria.
Xu X; Pu X; Jiang L; Huang Y; Yan L; Yang J; Wen T; Li B; Wu H; Wang W
J Cancer Res Clin Oncol; 2021 Feb; 147(2):607-618. PubMed ID: 32852635
[TBL] [Abstract][Full Text] [Related]
19. Outcome of ABO-incompatible adult living-donor liver transplantation for patients with hepatocellular carcinoma.
Yoon YI; Song GW; Lee SG; Hwang S; Kim KH; Kim SH; Kang WH; Cho HD; Jwa EK; Kwon JH; Tak EY; Kirchner VA
J Hepatol; 2018 Jun; 68(6):1153-1162. PubMed ID: 29452208
[TBL] [Abstract][Full Text] [Related]
20. Living donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation.
Xiao GQ; Song JL; Shen S; Yang JY; Yan LN
World J Gastroenterol; 2014 Aug; 20(31):10953-9. PubMed ID: 25152599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
